Thyroid Nodules

Few pieces of medical news set off alarm bells quite like the words "we found a nodule on your thyroid." Yet for the overwhelming majority of people, a thyroid nodule is one of the most common and least dangerous findings in all of medicine. A thyroid nodule is simply a lump — a discrete growth of cells — within the butterfly-shaped thyroid gland at the base of your neck. They are astonishingly common: with a modern ultrasound machine, doctors can find at least one nodule in somewhere between a fifth and two-thirds of ordinary adults, and the odds climb steadily with age. The single most important fact to hold onto while you read the rest of this page is that only a small minority of these lumps — roughly 5 to 15 percent — turn out to be cancer. The purpose of the workup that follows a nodule discovery is not to treat you as sick; it is to sort the small worrisome fraction from the large harmless majority, safely and with as little intervention as possible.

What Are Thyroid Nodules?
How Common Are They & Why Do They Form?
Symptoms (Usually None)
Are They Cancer? The Key Worry
How Nodules Are Diagnosed
Molecular Testing for Indeterminate Nodules
Treatment Options
Thyroid Cancer: A Brief Overview
Follow-Up & Monitoring
When to See a Doctor
Key Research Papers
Connections

What Are Thyroid Nodules?

The thyroid is a small gland, shaped like a butterfly or a bow tie, that wraps around the front of your windpipe just below the Adam's apple. Its job is to produce thyroid hormone, the master metabolic dial that sets how fast nearly every cell in your body runs. A nodule is any lump that arises within this gland and feels or looks different from the surrounding tissue. It may be solid, filled with fluid (a cyst), or a mixture of both.

Nodules are not a single disease but a category of many different things, most of them completely harmless:

Colloid nodules — overgrowths of normal thyroid tissue. These are the most common type and are never cancerous.
Thyroid cysts — fluid-filled sacs, often the remnant of a degenerated colloid nodule. Almost always benign.
Follicular adenomas — benign tumors of the thyroid's hormone-making cells.
Inflammatory nodules — lumps that form as part of chronic thyroid inflammation, such as Hashimoto's thyroiditis.
Hyperfunctioning ("hot") nodules — nodules that make thyroid hormone on their own, independent of the body's control signals. These can cause an overactive thyroid but are almost never cancerous.
Thyroid cancers — the small minority that require treatment, and the reason the workup exists.

When several nodules appear together, the gland is described as a multinodular goiter. Having many nodules rather than one does not raise the per-nodule cancer risk; each suspicious-looking nodule is simply evaluated on its own merits.

How Common Are They & Why Do They Form?

Thyroid nodules are one of the most frequent findings in clinical medicine, and they are being discovered more and more often — not because they are becoming more common, but because we image the neck so much more. A lump big enough to feel with the fingers is present in roughly 5 percent of women and 1 percent of men in parts of the world with adequate iodine. But when researchers scan random, symptom-free adults with high-resolution ultrasound, they find nodules in 19 to 68 percent of them, with the highest rates in women and in older people. Many nodules today are found completely by accident — a "thyroid incidentaloma" spotted on a carotid ultrasound, a neck CT, or a PET scan ordered for something else entirely.

Nodules become more likely as people age, and several factors push the odds higher:

Age — the prevalence rises steadily each decade; nodules are the norm, not the exception, in older adults.
Female sex — women develop nodules several times more often than men.
Iodine deficiency — historically a major driver of goiter and nodule formation worldwide.
Chronic inflammation — autoimmune thyroid disease such as Hashimoto's can produce nodular changes.
Radiation exposure — particularly radiation to the head, neck, or chest during childhood, which raises the risk of both nodules and thyroid cancer.
Family history and genetics — nodules and goiter tend to run in families.

Two nutrients are central to how the thyroid grows and functions. Chronic iodine deficiency drives the gland to enlarge and form nodules, while selenium is a cofactor for the enzymes that process thyroid hormone and dampen inflammation. Both are worth understanding, though neither is a treatment for an established nodule.

Symptoms (Usually None)

The most common "symptom" of a thyroid nodule is no symptom at all. The large majority are discovered by chance, either felt by a clinician during a routine exam or seen on an imaging test done for another reason. Most people carry a nodule for years without any awareness of it.

When nodules do cause trouble, it falls into a few recognizable patterns:

A visible or palpable lump. A larger nodule may be seen or felt as a swelling in the lower front of the neck that moves up and down when you swallow.
Compressive symptoms. A big nodule can press on neighboring structures: difficulty swallowing (a sense that food catches), a feeling of pressure or a lump in the throat, a nagging cough, or — less often — shortness of breath when a large goiter narrows the windpipe. New, persistent hoarseness deserves prompt attention because it can occasionally signal involvement of the nerve to the voice box.
Symptoms of an overactive thyroid. A hyperfunctioning ("hot") nodule pours out extra thyroid hormone. This can cause a racing or irregular heartbeat, unexplained weight loss, tremor, feeling hot and sweaty, anxiety, and trouble sleeping — the picture of hyperthyroidism.

Importantly, the size or presence of symptoms does not tell you whether a nodule is cancerous. Many cancers are small and silent; many large, uncomfortable nodules are entirely benign. That is exactly why the diagnostic workup relies on objective testing rather than on how a nodule feels.

Are They Cancer? The Key Worry

This is the question on everyone's mind, so let us answer it plainly: the great majority of thyroid nodules are benign. Across large studies, only about 5 to 15 percent of nodules turn out to be cancer, with the exact figure depending on a person's age, sex, radiation history, family history, and the nodule's appearance on ultrasound. Put the other way around, roughly 85 to 95 percent of nodules are not cancer — and even most of the cancers that are found are slow-growing and highly curable (see the overview below).

Rather than worry about every nodule equally, doctors look for specific features that raise the probability of cancer and warrant a closer look:

Age extremes — nodules found in children and in adults over about 60 carry somewhat higher risk.
Male sex — nodules are less common in men, but a nodule in a man is statistically a bit more likely to be malignant.
A history of radiation to the head or neck, especially in childhood.
A family history of thyroid cancer or of genetic syndromes such as multiple endocrine neoplasia type 2 (MEN2).
Rapid growth, a hard or fixed lump, persistent hoarseness, or enlarged lymph nodes in the neck.
Suspicious ultrasound features — a solid, markedly dark (hypoechoic) nodule with irregular margins, tiny bright spots (microcalcifications), or a shape that is taller than it is wide.

None of these findings means a nodule is cancer — they simply move it up the queue for evaluation. The workup that follows is designed to confirm the reassuring answer in the majority of cases while catching the treatable minority early.

How Nodules Are Diagnosed

The evaluation of a nodule follows a logical, stepwise path that has been refined over decades of guidelines. The goal at each step is to gather just enough information to make a safe decision without over-testing.

Step 1: A blood test for TSH

The first test is almost always a blood level of thyroid-stimulating hormone (TSH), the pituitary signal that tells the thyroid how hard to work. This inexpensive test, part of a standard thyroid panel, immediately splits the path in two:

If TSH is low (suppressed), the nodule may be making excess hormone. The next step is a radionuclide thyroid uptake scan, which shows whether the nodule is "hot" (overactive). Hot nodules are almost never cancerous, so a biopsy can usually be skipped and attention turns to managing the overactivity instead.
If TSH is normal or high, the nodule is "cold" or non-functioning, and evaluation proceeds to ultrasound.

Step 2: Thyroid ultrasound and risk stratification

Ultrasound is the workhorse of nodule evaluation — painless, radiation-free, and remarkably informative. It measures the nodule's size and describes its composition (solid vs. cystic), echogenicity (how dark or bright it appears), shape, margins, and any calcifications. Modern radiologists translate these features into a structured risk score. In the United States the dominant system is the American College of Radiology's TI-RADS (Thyroid Imaging Reporting and Data System), which assigns points for each feature and sorts nodules into categories from TR1 (benign) to TR5 (highly suspicious). Europe uses a parallel scheme called EU-TIRADS. These scores, combined with the nodule's size, determine whether — and when — a biopsy is warranted, sparing many low-risk nodules from unnecessary needles.

Step 3: Fine-needle aspiration biopsy

When a nodule's size and risk score cross the threshold, the definitive test is a fine-needle aspiration (FNA) biopsy. Using ultrasound for guidance, a doctor passes a very thin needle into the nodule and withdraws a few clusters of cells for a pathologist to examine. It is a quick office procedure, usually done with little or no anesthetic, and is far less involved than a surgical biopsy.

Step 4: The Bethesda System

Pathologists report FNA results using a standardized six-tier scheme called the Bethesda System for Reporting Thyroid Cytopathology. Each category carries an estimated risk of cancer, which drives what happens next:

Bethesda Category	Meaning	Approx. Cancer Risk
I	Nondiagnostic / unsatisfactory (too few cells)	Repeat the biopsy
II	Benign	About 0–3%
III	Atypia of undetermined significance (AUS/FLUS)	Roughly 10–30%
IV	Follicular neoplasm / suspicious for follicular neoplasm	Roughly 25–40%
V	Suspicious for malignancy	Roughly 50–75%
VI	Malignant	About 97–99%

The great value of this system is that most biopsies land in the reassuring benign (II) category and need only routine follow-up. The exact percentages have been refined over the years and vary somewhat between centers, but the tiers reliably rank a nodule from "almost certainly harmless" to "almost certainly cancer." The genuinely tricky cases are the indeterminate categories III and IV, which is where molecular testing has changed the game.

Molecular Testing for Indeterminate Nodules

Categories III and IV of the Bethesda system are frustrating: under the microscope the cells look ambiguous, and historically the only way to know for sure was to surgically remove part of the thyroid — even though most of these nodules turned out to be benign. That meant many people had diagnostic surgery they did not actually need.

Molecular testing was developed to solve this problem. These tests analyze the genetic material left over from the same FNA sample, looking for the mutations and gene-expression patterns that distinguish benign from cancerous thyroid cells. Two families of tests are widely used:

Gene-expression classifiers (the Afirma test) measure the activity of many genes at once. Their chief strength is a high negative predictive value — a "benign" result is reliable enough that surgery can often be safely avoided.
Mutation panels using next-generation sequencing (such as ThyroSeq) scan for specific cancer-associated DNA changes and gene fusions, providing both rule-out and rule-in information.

The practical payoff is substantial. In landmark studies, a benign molecular result on an indeterminate nodule was accurate enough to spare a large share of patients from an operation, while flagging the ones who genuinely needed surgery. Molecular testing does not replace the biopsy or the pathologist — it adds a layer of genetic information that turns many "we're not sure, let's operate" situations into confident, watch-and-wait decisions.

Treatment Options

The right treatment depends entirely on what the workup reveals. For most people, the answer is a pleasant surprise: no treatment at all beyond periodic checkups.

Active surveillance for benign nodules

A nodule that reads benign on biopsy and looks low-risk on ultrasound usually needs nothing more than watchful monitoring. Long-term studies show that most benign nodules stay the same size or grow only slowly over many years, and that growth by itself rarely signals cancer. Surveillance means an occasional ultrasound — the interval depends on the nodule's risk features — rather than any medication or procedure. The old practice of prescribing thyroid hormone to try to shrink benign nodules has largely been abandoned because the benefit is small and the risks of over-treatment are real.

When removal makes sense

Surgery to remove part or all of the thyroid (lobectomy or total thyroidectomy) is reserved for clear indications:

A biopsy showing cancer, or cytology suspicious enough to warrant it.
Compressive symptoms — difficulty swallowing or breathing from a large nodule or goiter.
Significant cosmetic concern from a visible neck mass.
Substantial growth or the development of worrisome features over time.

Radioactive iodine for hot nodules

A hyperfunctioning ("hot") nodule that is causing an overactive thyroid is typically treated with radioactive iodine (RAI), which the overactive tissue selectively absorbs and which quietly shrinks and switches it off over weeks to months. Surgery is an alternative, and anti-thyroid medications can control symptoms in the meantime. Because hot nodules are almost never cancerous, the aim here is to fix the hormone problem, not to remove a cancer.

Thermal ablation: a newer, less invasive option

For benign nodules that are causing symptoms but do not require full surgery, thermal ablation — most commonly radiofrequency ablation (RFA), and also laser or microwave techniques — has emerged as a minimally invasive alternative. A thin probe delivers controlled heat that shrinks the nodule from the inside, typically as an outpatient procedure, while preserving the rest of the thyroid and avoiding a surgical scar. It is increasingly offered at specialized centers for symptomatic benign nodules and for some hot nodules.

Thyroid Cancer: A Brief Overview

Because thyroid cancer is the fear that brings people to this page, it deserves a clear-eyed look — and the news is genuinely encouraging. Thyroid cancer is among the most treatable and survivable of all cancers. The main types are:

Papillary thyroid cancer — by far the most common (roughly 80–85% of cases), typically slow-growing, and with an excellent long-term outlook. For localized disease, survival is very high.
Follicular thyroid cancer — the next most common of the well-differentiated cancers, also generally treatable.
Medullary thyroid cancer — uncommon; can be sporadic or inherited (linked to MEN2), which is why family history matters.
Anaplastic thyroid cancer — rare and aggressive, but a small fraction of the total.

Treatment of the common differentiated cancers usually centers on surgery, sometimes followed by radioactive iodine, and most people do very well. There is an important nuance worth understanding: the sharp rise in thyroid cancer diagnoses over recent decades has been driven largely by overdiagnosis — the detection of tiny, harmless papillary cancers that would never have caused symptoms — rather than by a true epidemic of dangerous disease, since death rates have stayed largely flat. In response, guidelines now support active surveillance (careful monitoring instead of immediate surgery) for selected very-low-risk papillary microcarcinomas, sparing people the risks of an operation they may never have needed.

Follow-Up & Monitoring

For the many people whose nodule is benign, follow-up is straightforward and low-key. The typical pattern is a repeat ultrasound after an interval that depends on the nodule's risk score — higher-suspicion nodules are rechecked sooner, and clearly low-risk nodules can be followed less often or, for very benign-appearing ones, eventually not at all. The clinician watches for two things: meaningful growth and the appearance of any new suspicious features. If either occurs, a repeat FNA biopsy may be recommended.

A few practical points make monitoring less stressful:

Stable is good. A nodule that has not changed over years is very reassuring, and intervals between scans can often be stretched out.
Slow growth is usually benign. Modest enlargement is common with age and rarely means cancer, though it is what prompts a repeat look.
A single benign biopsy is highly reliable. Repeat biopsies are driven by change, not by the calendar.
Keep your records. Bringing prior ultrasound measurements to each visit lets your clinician compare accurately rather than relying on memory.

When to See a Doctor

Most nodules can be evaluated calmly and without urgency. Still, it is worth getting checked if you notice any of the following:

A new lump or swelling in the front of the neck, especially one you can see or feel move when you swallow.
Difficulty swallowing or breathing, or a persistent sensation of pressure or a lump in the throat.
New or worsening hoarseness that does not resolve, or a noticeable change in your voice.
A rapidly growing neck mass, or a lump that feels hard or is fixed in place.
Swollen lymph nodes in the neck alongside a thyroid lump.
Symptoms of an overactive thyroid (racing heart, unexplained weight loss, tremor, heat intolerance) or of an underactive thyroid (fatigue, weight gain, cold intolerance) — see hyperthyroidism and hypothyroidism.

If you have a personal history of radiation to the head or neck or a family history of thyroid cancer, mention it — it helps your clinician calibrate the workup. And if a nodule has already been evaluated and called benign, do not hesitate to ask when your next ultrasound is due so that monitoring does not slip through the cracks.

Key Research Papers

Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.
Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. Journal of the American College of Radiology. 2017;14(5):587-595.
Russ G, Bonnema SJ, Erdogan MF, et al. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. European Thyroid Journal. 2017;6(5):225-237.
Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341-1346.
Durante C, Costante G, Lucisano G, et al. The Natural History of Benign Thyroid Nodules. JAMA. 2015;313(9):926.
Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. New England Journal of Medicine. 2012;367(8):705-715.
Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120(23):3627-3634.
Steward DL, Carty SE, Sippel RS, et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. JAMA Oncology. 2019;5(2):204.
Vaccarella S, Franceschi S, Bray F, et al. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. New England Journal of Medicine. 2016;375(7):614-617.
Tan GH, Gharib H. Thyroid Incidentalomas: Management Approaches to Nonpalpable Nodules Discovered Incidentally on Thyroid Imaging. Annals of Internal Medicine. 1997;126(3):226-231.
Park HS, Baek JH, Park AW, et al. Thyroid Radiofrequency Ablation: Updates on Innovative Devices and Techniques. Korean Journal of Radiology. 2017;18(4):615.
Grani G, Lamartina L, Ascoli V, et al. Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS. Journal of Clinical Endocrinology & Metabolism. 2019;104(1):95-102.

Live PubMed Searches

These links open live PubMed searches for the listed keywords — results update as new studies are indexed.

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents